Search

A report from the Chinese Academy of Medical Sciences discusses the role of signaling lymphocytes activating molecule factors (SLAMFs) in regulating tumor immunity. The study found that SLAMF9 promotes tumor progression and suppresses immune therapy responses by reshaping the tumor microenvironment (TME). High levels of SLAMF9 expression were associated with poor prognosis and resistance to anti-PD-L1 therapy in certain cancer types. Knocking down SLAMF9 increased the sensitivity of melanoma to immunotherapy and improved survival in mice. This research highlights SLAMF9 as a potential target for reshaping the tumor immune microenvironment and improving the efficacy of immunotherapy. [Extracted from the article]

A study conducted by the University of Chicago Medicine examined the real-world persistence of successive biologics in patients with inflammatory bowel disease (IBD). The study analyzed data from the Optum Clinical Database and found that vedolizumab and infliximab had lower rates of switching or discontinuation compared to adalimumab as first-line biologics in patients with IBD. Additionally, vedolizumab, infliximab, and ustekinumab had lower rates of switching or discontinuation than adalimumab as second-line biologics. The study suggests that while anti-TNFa treatments were commonly prescribed, the adjusted rates of discontinuation for adalimumab were higher than for other biologics. [Extracted from the article]

Researchers at the Cancer Hospital have published a study on Regulatory T cells (Tregs) and their role in cancer immunotherapy. The study highlights how Tregs can suppress immune responses and potentially hinder antitumor immunity, making them a target for improving cancer treatment strategies. The research delves into the complex role of Tregs in cancer development, progression, and treatment, particularly in immune checkpoint blockade therapy. This study provides insights into therapies that target Tregs to enhance the effectiveness of cancer immunotherapy. [Extracted from the article]

A recent study conducted by the University of Chicago Medicine examined the outcomes of different sequences of biologic treatments in patients with inflammatory bowel disease (IBD). The study found that the choice of initial biologic treatment can impact the outcomes of later treatment lines. In patients with Crohn's disease (CD), the treatment sequence of ustekinumab to infliximab was associated with higher incidences of hospitalization, surgery, colorectal cancer (CRC), and infection. However, vedolizumab followed by an anti-tumor necrosis factor alpha (anti-TNFa) treatment was associated with a lower risk of adverse medical events. In patients with ulcerative colitis (UC), the treatment sequence of vedolizumab to adalimumab resulted in the lowest overall incidence of adverse outcomes. These findings provide potential guidance for clinicians in choosing sequences of biologic treatments for patients with IBD. [Extracted from the article]

A recent study conducted at a Cancer Hospital has revealed new findings on squamous cell carcinoma (SCC), the second most common type of lung cancer worldwide. The study focused on the role of Kallikrein-8 (KLK8) in SCC and its correlation with patient survival and immune response. The researchers found that high expression of KLK8 was associated with inferior survival and an immune-suppressive tumor microenvironment. These findings suggest that KLK8 could serve as a potential novel immune target for SCC treatment. Further research is needed to explore this possibility. [Extracted from the article]

Keywords: Cancer; Drugs and Therapies; Health and Medicine; Immunotherapy; Oncology; Risk and Prevention; Solid Cancer EN Cancer Drugs and Therapies Health and Medicine Immunotherapy Oncology Risk and Prevention Solid Cancer 1205 1205 1 10/16/23 20231017 NES 231017 2023 OCT 17 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Current study results on solid cancer have been published. Survival analysis revealed that the clinical outcome of HPD patients was significantly worse than non-HPD patients. [Extracted from the article]

The news reporters obtained a quote from the research from Cancer Hospital: "Kruppel-like factor 12 (KLF12) is a transcriptional inhibitor whose role in tumor immunity is unclear. Keywords: Antiparasitics; Cancer; Drugs and Therapies; Galectin 1; Galectins; Health and Medicine; Immunology; Immunotherapy; Lectins; Oncology; Pharmaceuticals; Proteins EN Antiparasitics Cancer Drugs and Therapies Galectin 1 Galectins Health and Medicine Immunology Immunotherapy Lectins Oncology Pharmaceuticals Proteins 946 946 1 08/28/23 20230829 NES 230829 2023 AUG 29 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on cancer are discussed in a new report. [Extracted from the article]

Cancer, Drugs and Therapies, Genetics, Health and Medicine, Immunology, Immunotherapy, Oncology Keywords: Cancer; Drugs and Therapies; Genetics; Health and Medicine; Immunology; Immunotherapy; Oncology EN Cancer Drugs and Therapies Genetics Health and Medicine Immunology Immunotherapy Oncology 1256 1256 1 08/21/23 20230822 NES 230822 2023 AUG 22 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- New research on cancer is the subject of a new report. [Extracted from the article]

Cancer, Drugs and Therapies, Health and Medicine, Oncology Keywords: Cancer; Drugs and Therapies; Health and Medicine; Oncology EN Cancer Drugs and Therapies Health and Medicine Oncology 810 810 1 08/14/23 20230815 NES 230815 2023 AUG 15 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- A new study on cancer is now available. [Extracted from the article]